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Background: The objective of this study was to assess the impact of antimicrobial stewardship programs on
the multidrug resistance patterns of bacterial isolates. The study comprised an initial retrospective analysis of
multidrug resistance in bacterial isolates for one year (July 2007-June 2008) followed by prospective
evaluation of the impact of Antimicrobial Stewardship programs on resistance for two years and nine months
(July 2008-March 2011).
Setting: A 300-bed tertiary care private hospital in Gurgaon, Haryana (India)
Findings: Methods: Study Design
 July 2007 to June 2008: Resistance patterns of bacterial isolates were studied.
 July 2008: Phase I intervention programme Implementation of an antibiotic policy in the hospital.
 July 2008 to June 2010: Assessment of the impact of the Phase I intervention programme.
 July 2010 to March 2011: Phase II intervention programme: Formation and effective functioning of the
antimicrobial stewardship committee. Statistical correlation of the Defined daily dose (DDD) for
prescribed drugs with the antimicrobial resistance of Gram negatives.
Results: Phase I intervention programme (July 2008) resulted in a decrease of 4.47% in ESBLs (E.coli and
Klebsiella) and a significant decrease of 40.8% in carbapenem-resistant Pseudomonas. Phase II intervention
(July 2010) brought a significant reduction (24.7%) in carbapenem-resistant Pseudomonas. However, the
resistance in the other Gram negatives (E.coli, Klebsiella, and Acinetobacter) rose and then stabilized. A
positive correlation was observed in Pseudomonas and Acinetobacter with carbapenems and
cefoperazone-sulbactam.
Piperacillin-tazobactam showed a positive correlation with Acinetobacter only. E.coli and Klebsiella showed
positive correlation with cefoparazone-sulbactam and piperacillin-tazobactam.
Conclusion: An antimicrobial stewardship programme with sustained and multifaceted efforts is essential
to promote the judicious use of antibiotics.
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Introduction
Antimicrobial resistance is not a new phenomenon;
however, the current magnitude and the speed with
which it is developing is a cause for global concern in-
cluding in India.
Multidrug resistant organisms (MDROs) are defined
as microorganisms that are resistant to one or more
classes of antimicrobial agents (e.g., ESBL, MRSA, VRE
etc.) [1]. These highly resistant organisms deserve special
attention in healthcare facilities as they are associated
with increased lengths of stay, costs, and mortality [1].
They can also be transmitted between patients and
healthcare workers and lead to the spread of antimicro-
bial resistance. In most instances, MDRO infections have
clinical manifestations that are similar to infections
caused by susceptible pathogens. However, options for
treating these infections are often extremely limited.
The current need is to develop a robust antimicrobial
stewardship programme which would enhance clinical
outcomes, reduce non-judicious use of antibiotics and
healthcare costs and minimize adverse effects of anti-
microbial use (toxicity and resistance). Furthermore, an
effective infection control program should be put in
place for reducing the transmission of drug-resistant
bacteria within the hospital. This should be developed at
the local level in hospitals and a national level. A start
has been made in India in terms of developing a Na-
tional Policy for Containment of Antimicrobial Resist-
ance by the Directorate General of Health Services in
which a special task force has been created to fulfill the
objectives above.Materials and methods
The present study was conducted in a 300-bed tertiary
care private hospital in Gurgaon, Haryana (India). The
bacterial culture data of all samples was analyzed for a
total period of 45 months (3 years and 9 months) (July
2007 to March 2011) in the Microbiology laboratory of
the hospital. Standard culture methods were used (Prac-
tical Medical Microbiology 14th ed. by Colle and Fraser)
and the isolates, both Gram positive and Gram negative
were processed for identification and antibiotic suscepti-
bility tests using VITEKW 2 Compact system (bioMér-
ieux, Marcy l’Etoile, France), following CLSI guidelines
[2-4]. The antibiogram of each confirmed isolate was
studied and susceptibility results were compiled using
the WHONET 5.4 programme.
Our study was divided into four stages:
 July 2007 to June 2008: Resistance patterns of
Gram-negative isolates- E.coli, Klebsiella,
Pseudomonas and Acinetobacter were studied. July 2008: Phase I intervention programme:
Implementation of an antibiotic policy in the
hospital. In addition, Infection control practices,
such as hand hygiene, a clean environment,
appropriate infection barriers and early identification
and isolation of patients infected with a
transmissible microorganism were also promoted
through regular training sessions of the healthcare
staff.
 July 2008 to June 2010: Assessment of the impact of
the Phase I intervention programme.
 July 2010 to March 2011: Phase II intervention
programme: This included the formation and
effective functioning of the antimicrobial
stewardship committee.
Defined daily dose (DDD) per 1,000 inpatient-days for
each drug (Cefoparazone/Sulbactam, Piperacillin/
Tazobactam and Carbapenems{imipenem and merope-
nem}) prescribed every month was calculated according to
the World Health Organization (WHO) anatomical thera-
peutic chemical (ATC) classification system 2009 [5]. This
was statistically correlated with the antimicrobial resistance
of E.coli, Klebsiella, Pseudomonas and Acinetobacter
expressed as incidence density/1000 inpatients to deter-
mine the significance of the analysis.
Results and discussion
Infectious diseases continue to be a leading cause of
mortality the world over and more so in developing
countries with low access to health services (World
Health Report 2007) [6].
The results of the bacterial cultures performed over a
period of 45 months (July 2007 to March 2011) in the
Microbiology lab of a tertiary care private hospital in
Gurgaon, Haryana, India are tabulated (Table 1).
A total of 28 971 samples were cultured. The break-up
into the various sample types showed that urine cultures
were the predominant sample (10 970 out of 28 971)
representing 37.86% of the total number.
A total of 5615 isolates were obtained from 28 971
cultures, giving a 19.38% culture yield. Out of the total
isolates, 4539 were Gram-negative showing a clear pre-
ponderance of Gram-negative pathogens in the hospital en-
vironment (80.8%). 19.9% comprised the Gram-positive
load (1076 out of 5615).
Among the Gram-negative isolates, E.coli (43.9%), Kleb-
siella (19.7%), Pseudomonas (15.1%) and Acinetobacter
(9.69%) were the predominant isolates overall. The anti-
biograms showed the combined extended spectrum
β-lactamases (ESBL) prevalence of 55.3% which
included both E.coli and Klebsiella with 54.2% and
57.9% respectively. The prevalence of carbapenem
Table 1 Total Cultures from July 2007 - Mar 2011
Period Total Samples Break-up Total Positives Gram Negatives Gram Positives
July 2007 -March 2011 28971 Urine 10970 (37.8%) 2035 1785 250
Blood 9386 920 676 244
Respiratory 3865 1300 1136 164
Pus 1601 854 505 349
Stool 1368 357 354 3
Fluids 1781 149 83 66
28971 5615 4539 (80.8%) 1076 (19.1%)
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found to be 27.7% and 85% respectively (Table 2).
In India, various studies have shown the prevalence of
ESBL in E.coli and Klebsiella to range from 20% to 60%
[7-9]. The carbapenem resistance range reported in
Pseudomonas was 26-43% [10-12] and in Acinetobacter,
21-39% [13-15].
Among the Gram positives, Staphylococcus aureus (36.8%),
Coagulase negative Staphylococci (19.8%) and Enterococci
(38.1%) were the predominant isolates (Additional file 1:
Table S1). Of these isolates, the prevalence of Methicillin-
resistant Staphylococcus aureus (MRSA) was 36.27%, Methi-
cillin-resistant Coagulase-negative Staphylococci (MRSE) was
67.75% and Vancomycin-resistant Enterococci (VRE) was
6.58% overall (Table 3).
According to our staged intervention plan, the resistance
data of Gram-negative isolates (E.coli, Klebsiella, Pseudo-
monas and Acinetobacter) and Gram-positive isolates
(Staphylococcus aureus, Coagulase-negative Staphylococci
and Enterococci,) were retrospectively analyzed over a one-
year period (July 2007 to June 2008). During thisTable 2 Antimicrobial Resistance of Gram-negative Organism

































167 106 111 83 189 (67.9%) 43
(63.4%) (74.7%)
Total 1997 1091 898 520 1602
(55.3%)
440
(54.6%) (57.9%)period, the overall ESBL prevalence in E.coli and Klebsiella
was 53.6% and the percentage resistance to carbapenems in
Pseudomonas and Acinetobacter was found to be 21.3%
and 12.5%, respectively (Table 2). Among the Gram-
positive isolates, MRSA showed a prevalence of
28.3%, MRSE 72.72% and VRE 3.9%. This data is
shown in Table 3.
Phase I intervention programme
The Phase I intervention programme under which the
antibiotic policy was introduced and implemented was
initiated in July 2008. After assessing the impact of the
program, it was observed that the resistance patterns of
the isolates for the first 6 months (July 2008- Dec 2008)
showed a minor decrease of 4.47% in combined ESBL
prevalence in E.coli and Klebsiella and also a significant
decrease of 40.8% in carbapenem resistance towards
Pseudomonas. However, there was a significant increase
in resistance in Acinetobacter. This could be because of
a lowering of infection control standards or the entry of










2 (12.5%) 89 19 (21.3%)
17 (63%) 79 10 (12.6%)
121 (88.9%) 294 97 (32.9%)
89 (87.2%) 86 30 (34.8%)
104 (89.6%) 99 24 (24.2%)
41 (95.3%) 42 11 (26.2%)
374 (85%) 689 191(27.7%)
Table 4 Correlation analysis between Antibiotic
prescription and Antimicrobial resistance (July 2010-






















Table 3 Antimicrobial Resistance of Gram-positive Organisms








July 2007-June 2008 53 15 (28.3%) 22 16 (72.72%) 102 4 (3.9%)
July 2008- Dec 2008 48 14 (29.2%) 21 4 (19.04%) 39 6 (15.3%)
Jan 2009- Dec 2009 135 51 (37.7%) 57 49 (85.9%) 107 6 (5.60%)
Jan 2010- Jun 2010 55 19 (34.5%) 49 33 (67.3%) 52 7 (13.4%)
July 2010- Dec 2010 74 26 (35.1%) 41 28 (68.2%) 89 4 (4.49%)
Jan 2011 - Mar 2011 32 19 (59.3%) 24 14 (62.5%) 21 3 (14.28%)
Total 397 144 (36.2%) 214 144 (67.2%) 410 30 (7.3%)
* - Methicillin-resistant Staphylococcus aureus.
** - Methicillin-resistant coagulase-negative Staphylococci.
*** - Vancomycin-resistant Enterococci.
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ing year (2009) for ESBLs (E.coli and Klebsiella) showing a
significant decrease of 14.1% but the next six months (Jan
2010-June 2010) showed an increase of 36% bringing the
ESBL prevalence up to 62.6%. The carbapenem resistance
in Pseudomonas and Acinetobacter showed a substantial
increase in the year 2009 followed by a minor decrease of
5.7% and 1.9% respectively over the next six months. This
probably indicated an urgent need for further intervention
as it was felt that the impact of the Phase I intervention
was waning.
Phase II intervention programme
The Phase II intervention programme was initiated in July
2010 as the Antimicrobial Stewardship Programme based
on IDSA (Infectious Diseases Society of America) guide-
lines [16]. This stage comprised the formation and effective
functioning of the antimicrobial stewardship committee.
The function of this committee was to optimize clinical
outcome and minimize unintended consequences of
antimicrobial use, namely toxicity and selection of drug-
resistant pathogens, and to modify existing antibiotic guide-
lines as required depending on the antibiograms and
discussion with physicians. It also included a prospective
audit with intervention, feedback, formulary restriction and
preauthorization which were implemented in combination
with rigorous infection control policies and protocols to
prevent the further spread of multi-resistant pathogens.
Similar components of antimicrobial stewardship interven-
tions were recommended by Patel et al. [17]
The impact of stewardship programs on antimicrobial
use has been summarized in many study reviews [18,19].
In our study, a significant decrease of 24.7% was only
observed in the case of carbapenem-resistant Pseudomonas
in the nine-month period from July 2010 to March 2011.
The rest of the resistance patterns remained fairly stable,
possibly indicating that a more prolonged time periodis required to have an impact. It may also indicate the nat-
ural evolution of antimicrobial resistance.
The results of Gram-positive organisms, namely MRSA,
MRSE and VRE, did not show any significant correlation
with the intervention programmes, and considering that
they do not form a major part of the total isolates, their
in-depth analysis is beyond the purpose of this paper.
However, their detailed results are shown in Additional
file 1: Table S1.Correlation of antimicrobial consumption with
resistance
ICU is a high antibiotic usage area; therefore, a correlation
was simultaneously sought between antibiotic usage
Figure 1 Antimicrobial Resistant A cinetobacter & Pseudonomas isolates and respective Carbapenem prescription volumes form Jul'10
to Mar'11 in ICU.
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sistance patterns in the phase II post-intervention period
(July 2010 to March 2011) (Table 4). A positive correlation
was observed with carbapenem (imipenem and merope-
nem) and cefoperazone-sulbactam usage and the develop-
ment of resistance in Acinetobacter and Pseudomonas.
However, Piperacillin-tazobactam showed a positive correl-
ation with Acinetobacter but a negative correlation with
Pseudomonas.
In E.coli and Klebsiella, a positive correlation was
observed with the usage of cefoperazone-sulbactam and
piperacillin-tazobactam, however a negative correlation
was seen with the usage of carbapenems (imipenem and
meropenem) and the development of resistance to theseFigure 2 Antimicrobial Resistant E, coli & Kleb isolates (%) and respec
Antibiotic prescription volume form Jul'10 to Mar'11 in ICU.antibiotics (see Figures 1 and 2). There are several pos-
sible explanations for the lack of significant correlation
between antibiotic prescription and resistance in our
study. As may be pointed out, resistance selection pres-
sure occurs at the individual level and calculating anti-
biotic prescription using DDD measurements does not
measure individual exposure to antibiotics [20].
In conclusion, our data demonstrated correlation
between antibiotic prescription and Gram-negative
bacterial resistance to several, but not all, key anti-
microbial agents in the hospital. In areas where
Gram-negative bacterial resistance is endemic and
prescription of broad-spectrum antimicrobial agents
is high, factors other than antimicrobial usage maytive Piperacillin/Tazobactam & Cefoparazone/Sulbactam
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rates [21].
The natural march of resistance and the entry of more
drug-resistant organisms in the tertiary care centre also
play a role in increasing overall resistance percentages.
Our study highlights the increasing resistance in
Gram-negative bacteria towards antibiotics in our hos-
pital. As this study was limited to the antibiotic-resistant
bacteria isolated from patients in the tertiary care hos-
pital, the true extent of resistance to these agents among
bacterial isolates from community-acquired infections is
not clear. Also an attempt should be made to risk-strat-
ify the patients into three types; type 1 being patients
who have had no prior antibiotic treatment or contact
with the healthcare system, young patients with few co-
morbid conditions, Type 2 as recent admission with
short antibiotic therapy and older patients and Type 3 as
long hospitalization, multiple antibiotic therapies and
immunocompromised state.
Antimicrobial stewardship programs are clearly
required in hospitals to promote and emphasize the ra-
tional use of antimicrobials. Although resistance is a
worldwide concern, it is first and foremost a local prob-
lem: selection and amplification of resistant members of
a species are occurring in individual hospitals (and com-
munities), which can then spread worldwide [22]. An ef-
fective infection control program can make a significant
contribution to limiting the spread of resistance. How-
ever, in the present study, the gaps in the infection con-
trol program due to the higher turnover rate of the
nursing staff, regular admission of patients infected with
resistant strains into the hospital and the high endem-
icity of drug-resistant pathogens in the region could ex-
plain the limited impact of the antimicrobial stewardship
actions undertaken in this hospital.
Additional file
Additional file 1: Table S1. Gram Positive Culture data of various
samples from July 2007 to March 2011.
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